3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
2
Phase 3
2
Phase 2
2
Phase 1
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
120
Lymphoma
90
Lymphoma, Large B-Cell, Diffuse
79
Precursor Cell Lymphoblastic Leukemia-Lymphoma
34
Burkitt Lymphoma
31
Multiple Myeloma
26
Lymphoma, Non-Hodgkin
26
Lymphoma, Follicular
26
Leukemia
26
Hodgkin Disease
24
Lymphoma, Mantle-Cell
18
Neoplasms
16
Lymphoma, T-Cell, Peripheral
16
Lymphoma, B-Cell
14
Lymphoma, Large-Cell, Immunoblastic
12
Lymphoma, Large-Cell, Anaplastic
11
Dendritic Cell Sarcoma, Interdigitating
10
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
9
Recurrence
8
Lymphoma, B-Cell, Marginal Zone
8
Leukemia, Lymphocytic, Chronic, B-Cell
8
Neoplasms, Plasma Cell
7
Neoplasm Metastasis
7
Waldenstrom Macroglobulinemia
6
Primary Myelofibrosis
6
Lymphoma, T-Cell
6
Immunoblastic Lymphadenopathy
6
HIV Infections
5
Graft vs Host Disease
5
Blast Crisis
5
Interventions
enzalutamide
4
cabazitaxel
3
Docetaxel
3
Prednisone
2
talazoparib
1
rucaparib
1
pembrolizumab
1
olaparib
1
Zuclomiphene
1
XRP6258
1
Standard of Care
1
Radiosurgery
1
Positron Emission Tomography Computed Tomography
1
LY3023414
1
Injections
1
Carboplatin
1
Abituzumab
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Prostate Cancer Metastatic
×
Prednisone
×
Clear all
NCT02379390
2019-06-21
PRIMCAB
Sanofi
Phase 2
Terminated
8 enrolled
8 charts
NCT01718353
2017-11-20
TAXYNERGY
Sanofi
Phase 2
Completed
63 enrolled
13 charts